myTomorrows Expands Clinical Trial Search Capabilities
The myTomorrows platform has made significant strides in enhancing the experience for healthcare professionals seeking clinical trials and Expanded Access Programs. The latest integration introduces AI-powered eligibility checking that streamlines the process and improves usability.
Integration with ISRCTN Registry
myTomorrows has announced a crucial update: the inclusion of the ISRCTN registry to its clinical trial search functionality. This means the platform now pulls data from an even more diverse set of global registries, including trusted sources like clinicaltrials.gov and EudraCT. The result is an extensive and unbiased overview of clinical trials available worldwide.
Importance of ISRCTN Registry
The ISRCTN registry has become particularly relevant for UK-focused trials since Brexit, as it hosts non-commercial studies that may not be listed in other databases. This empowers healthcare professionals with localized data, ensuring they can find clinical trials registered specifically with ISRCTN, thus addressing the needs of patients in their care.
Usability Improvements and AI Matching
In addition to broadening the clinical trial search, the myTomorrows platform features numerous usability enhancements. The integrated AI assistant effectively pre-screens trial options by matching individual patient profiles to trial eligibility criteria. This advancement saves valuable time for healthcare professionals by reducing search and screening times by up to 90%.
Facilitating Comprehension of Related Trials
The platform is not just limited to primary conditions; it allows healthcare professionals to perform searches across multiple countries and for related diseases. This unique functionality ensures that HCPs can uncover pertinent trials for similar health conditions, enriching their resource pool for patient treatment options.
Current Insights on Clinical Research
Another exciting addition to the myTomorrows platform is the feature that offers insights into ongoing clinical research findings about developmental treatments. This resource provides summaries concerning the efficacy, safety, and mechanisms of drugs in their corresponding trials, facilitating informed decisions for physicians regarding trial suitability for their patients.
CEO’s Vision for myTomorrows
Michel van Harten, MD, CEO of myTomorrows, emphasized the platform's role as a comprehensive tool for healthcare professionals. He noted that the updates are designed to fulfill HCPs' needs for reliable trial information—an essential element in bridging information gaps and improving patient referrals.
Global Reach and Support for Patients
As a registered ICO entity, myTomorrows has assisted over 14,000 patients and 2,100 physicians globally in discovering and accessing pre-approval treatment options. The platform complies with ISO27001 and GDPR regulations, enabling healthcare professionals to seamlessly navigate a maze of public clinical trial registries, making patient referrals more efficient.
Patient Navigators Assistance
Patients and their families benefit significantly from the support provided by myTomorrows' team of trained Patient Navigators. These professionals guide them through the often complex treatment discovery process, ensuring that they have access to necessary information and resources.
About myTomorrows
myTomorrows stands as a global health technology leader dedicated to removing barriers for patients in search of diverse treatment options. The company leverages robust technology to facilitate a comprehensive exploration of clinical trials, effectively connecting patients, physicians, trial sites, and Biopharma. Based in Amsterdam, with an office in New York City, myTomorrows has positively impacted the lives of thousands of patients across more than 40 countries.
Frequently Asked Questions
What is the purpose of myTomorrows?
myTomorrows helps connect patients to pre-approval treatment options and improves access to clinical trials.
How does the AI aspect of myTomorrows enhance user experience?
The AI assistant simplifies the identification of suitable clinical trials by pre-screening patient medical profiles against eligibility criteria, saving time.
Why is the ISRCTN registry significant for UK clinical trials?
Since Brexit, ISRCTN has become crucial for UK-centric studies, particularly for non-commercial trials that may not be available in other registries.
What support does myTomorrows offer to patients and families?
myTomorrows provides guidance through a team of Patient Navigators, helping families navigate the process of finding suitable treatment options.
How has myTomorrows expanded its platform capabilities?
The platform now includes enhanced search functionality for related diseases, multi-country trials, and insights into current clinical research findings.
